Literature DB >> 7693944

14 beta-[(p-nitrocinnamoyl)amino]morphinones, 14 beta-[(p-nitrocinnamoyl)amino]-7,8-dihydromorphinones, and their codeinone analogues: synthesis and receptor activity.

A Sebastian1, J M Bidlack, Q Jiang, D Deecher, M Teitler, S D Glick, S Archer.   

Abstract

A series of 14 beta-[(nitrocinnamoyl)amino]codeinones and morphinones, some of which contain a 5 beta-methyl group, were prepared from 14 beta-aminocodeinones and 14 beta-[N-(cyclopropylmethyl)-amino]norcodeinones. The affinities of the target compounds for the mu, delta, and kappa opioid receptors were determined by radiolabeled binding experiments using bovine brain membranes. An analogous series of 7,8-dihydrocodeinones and morphinones was prepared and assayed in the same systems. The 3-methoxy derivatives 3 and 4 were more selective than the corresponding morphinones for the mu receptor. The 5 beta-methylcodeinones 25 and 27 had lower affinity at all receptors than the corresponding morphinones, but the 5 beta-methylmorphinones had affinities similar to the morphinones 5 and 6. A similar pattern was observed in the 7,8-dihydro series. Two compounds, 5 beta-methyl-14 beta-[(p-nitrocinnamoyl)amino]-7,8-dihydromorphinone, 20 (MET-CAMO), and N-(cyclopropylmethyl)-14 beta-[(p-nitrocinnamoyl)amino]-7,8-dihydronormorphinone, 22 (N-CPM-MET- CAMO), acted as nonequilibrium ligands in antinociception and membrane binding studies. In mice after icv administration, neither ligand showed any agonist activity but 8-24 h after administration both compounds acted as potent mu antagonists. A Scatchard plot of the effect of N-CPM-MET-CAMO on [3H]DAMGO ([3H]D-Ala2, (Me)-Phe4, Gly(ol)5] enkephalin) binding to bovine striatal membranes showed that there was a significant decrease in the Bmax value and a marginal effect on the Kd value suggesting that the number of binding sites was reduced. When taken together, these results support the view that 20 and 22 bind covalently to the mu receptor. On the other hand, when N-acetylcysteine and 22 were allowed to react in a buffered solution, 22 was recovered unchanged. Under these conditions no Michael reaction was observed.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7693944     DOI: 10.1021/jm00073a015

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  8 in total

Review 1.  Homology modeling of opioid receptor-ligand complexes using experimental constraints.

Authors:  Irina D Pogozheva; Magdalena J Przydzial; Henry I Mosberg
Journal:  AAPS J       Date:  2005-10-05       Impact factor: 4.009

2.  14beta-Arylpropiolylamino-17-cyclopropylmethyl-7,8-dihydronormorphinones and related opioids. Further examples of pseudoirreversible mu opioid receptor antagonists.

Authors:  Nick P R Nieland; David Rennison; Jillian H Broadbear; Lauren Purington; James H Woods; John R Traynor; John W Lewis; Stephen M Husbands
Journal:  J Med Chem       Date:  2009-11-12       Impact factor: 7.446

3.  Structural determinants of opioid activity in derivatives of 14-aminomorphinones: effect of substitution in the aromatic ring of cinnamoylaminomorphinones and codeinones.

Authors:  Nick P R Nieland; Humphrey A Moynihan; Simon Carrington; Jillian Broadbear; James H Woods; John R Traynor; Stephen M Husbands; John W Lewis
Journal:  J Med Chem       Date:  2006-08-24       Impact factor: 7.446

4.  Pharmacological mechanisms underlying the antinociceptive and tolerance effects of the 6,14-bridged oripavine compound 030418.

Authors:  Quan Wen; Gang Yu; Yu-lei Li; Ling-di Yan; Ze-hui Gong
Journal:  Acta Pharmacol Sin       Date:  2011-08-22       Impact factor: 6.150

5.  Structural determinants of opioid activity in derivatives of 14-aminomorphinones: effects of changes to the chain linking of the C14-amino group to the aryl ring.

Authors:  David Rennison; Humphrey Moynihan; John R Traynor; John W Lewis; Stephen M Husbands
Journal:  J Med Chem       Date:  2006-10-05       Impact factor: 7.446

6.  Opioid receptor selectivity profile change via isosterism for 14-O-substituted naltrexone derivatives.

Authors:  Yan Zhang; Orgil Elbegdorj; Yunyun Yuan; Irina O Beletskaya; Dana E Selley
Journal:  Bioorg Med Chem Lett       Date:  2013-05-16       Impact factor: 2.823

7.  14 beta-O-cinnamoylnaltrexone and related dihydrocodeinones are mu opioid receptor partial agonists with predominant antagonist activity.

Authors:  H Moynihan; A R Jales; B M Greedy; D Rennison; J H Broadbear; L Purington; J R Traynor; J H Woods; J W Lewis; S M Husbands
Journal:  J Med Chem       Date:  2009-03-26       Impact factor: 7.446

8.  Selective and Wash-Resistant Fluorescent Dihydrocodeinone Derivatives Allow Single-Molecule Imaging of μ-Opioid Receptor Dimerization.

Authors:  Christian Gentzsch; Kerstin Seier; Antonios Drakopoulos; Marie-Lise Jobin; Yann Lanoiselée; Zsombor Koszegi; Damien Maurel; Rémy Sounier; Harald Hübner; Peter Gmeiner; Sébastien Granier; Davide Calebiro; Michael Decker
Journal:  Angew Chem Int Ed Engl       Date:  2020-01-07       Impact factor: 16.823

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.